公开(公告)号：US10421789B2

公开(公告)日：2019-09-24

申请号：US16291726

申请日：2019-03-04

Applicant: University of Washington, Center for Commercialization ,  The Scripps Research Institute ,  International AIDS Vaccine Initiative

Inventor： Po-Ssu Huang ,  Joseph Graham Jardine ,  Sergey V. Menis ,  William Ray Schief ,  Neil P. King

IPC: A61K39/00 ,  A61K39/21 ,  C07K16/10 ,  A61K39/12 ,  C07K14/005 ,  G01N33/564 ,  A61K38/00

Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.

公开(公告)号：US09630994B2

公开(公告)日：2017-04-25

申请号：US14930792

申请日：2015-11-03

Applicant: UNIVERSITY OF WASHINGTON

Inventor： David Baker ,  Jacob B. Bale ,  Neil P. King ,  William H. Sheffler ,  Daniel Ellis

IPC: A61K38/16 ,  C07K14/00

CPC classification number: C07K14/00

Abstract: Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.

公开(公告)号：US12275757B2

公开(公告)日：2025-04-15

申请号：US18337881

申请日：2023-06-20

Applicant: University of Washington ,  INSTITUTE FOR RESEARCH IN BIOMEDICINE

Inventor： Neil P. King ,  David Baker ,  Brooke Fiala ,  Lance Joseph Stewart ,  Laurent Perez ,  Antonio Lanzavecchia ,  Jessica Marcandalli ,  Jorge Fallas ,  Yang Hsia

IPC: A61K39/12 ,  A61K39/00 ,  A61K39/155 ,  A61K39/385 ,  A61P31/14 ,  B82Y5/00 ,  C07K14/005 ,  C12N7/00

Abstract: Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

公开(公告)号：US11192926B2

公开(公告)日：2021-12-07

申请号：US16500331

申请日：2018-04-03

Applicant: UNIVERSITY OF WASHINGTON ,  INSTITUTE FOR RESEARCH IN BIOMEDICINE

Inventor： Neil P. King ,  David Baker ,  Brooke Nickerson ,  Lance Joseph Stewart ,  Laurent Perez ,  Antonio Lanzavecchia ,  Jessica Marcandalli

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  C07K14/005 ,  A61K39/385 ,  A61P31/14 ,  B82Y5/00 ,  C12N7/00

Abstract: Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructures; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

公开(公告)号：US10221217B2

公开(公告)日：2019-03-05

申请号：US14978132

申请日：2015-12-22

Applicant: University of Washington, Center For Commercialization ,  The Scripps Research Institute ,  International AIDS Vaccine Initiative

Inventor： Po-Ssu Huang ,  Joseph Graham Jardine ,  Sergey V. Menis ,  William Ray Schief ,  Neil P. King

IPC: A61K39/00 ,  A61K39/21 ,  A61K39/12 ,  C07K14/005 ,  C07K16/10 ,  A61K38/00 ,  G01N33/564

Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.

公开(公告)号：US20160185825A1

公开(公告)日：2016-06-30

申请号：US14978132

申请日：2015-12-22

Applicant: University of Washington, Center For Commercialization ,  The Scripps Research Institute ,  International AIDS Vaccine Initiative

Inventor： Po-Ssu Huang ,  Joseph Graham Jardine ,  Sergey V. Menis ,  William Ray Schief ,  Neil P. King

IPC: C07K14/005

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/12 ,  A61K39/21 ,  C12N2740/16122 ,  C12N2740/16134 ,  G01N33/564

Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.

Abstract translation: 本发明涉及HIV gp120的工程外结构域（eOD）及其突变体及其制备和使用方法。 突变体eOD可有利于引发CD4结合位点（CD4b） - 定向广泛中和抗体（bnAb）和/或改善与成熟VRC01的结合和/或改善与种系VRC01和其他VH1-2的种系的结合 衍生的广泛中和抗体。 突变体eOD还可以包括eOD上的聚糖掩蔽突变。 本发明还包括将eOD融合到各种蛋白质多聚体以增强免疫原性，以及设计代表VRC01表位和周围环境中HIV序列的完整多样性的不同eOD的鸡尾酒。

公开(公告)号：US20240277831A1

公开(公告)日：2024-08-22

申请号：US17760174

申请日：2021-02-12

Applicant: University of Washington

Inventor： Neil P. King ,  David Veesler ,  Carl Walkey ,  Alexandra C. Walls ,  Jing Yang Wang

IPC: A61K39/215 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005

CPC classification number: A61K39/215 ,  A61P31/14 ,  C07K14/005 ,  A61K2039/55555 ,  A61K2039/575 ,  C12N2770/20022 ,  C12N2770/20034

Abstract: Disclosed herein are polypeptides comprising an amino acid sequence at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-84, 138-146, and 167-184, nanoparticles thereof, related nanoparticle compositions, and their use to treat or limit development of an infection.

公开(公告)号：US11866699B2

公开(公告)日：2024-01-09

申请号：US16476917

申请日：2018-02-12

Applicant: UNIVERSITY OF WASHINGTON

Inventor： Marc Joseph Lajoie ,  Elizabeth Erin Gray ,  Neil P. King ,  Daniel Brewster Stetson ,  David Baker ,  Katherine DaPron

IPC: C07H21/04 ,  C12N15/11 ,  C07K14/005 ,  C12N9/22 ,  C12N15/85

CPC classification number: C12N15/11 ,  C07K14/005 ,  C12N9/22 ,  C12N15/111 ,  C12N15/85 ,  C12Y301/21 ,  C12N2310/20 ,  C12N2800/80 ,  C12Q2521/301

Abstract: The application discloses multimeric assemblies packaging one or more active component and their use to carry out nucleic acid regulation or gene editing.

公开(公告)号：US11732011B2

公开(公告)日：2023-08-22

申请号：US17523174

申请日：2021-11-10

Applicant: UNIVERSITY OF WASHINGTON ,  INSTITUTE FOR RESEARCH IN BIOMEDICINE

Inventor： Neil P. King ,  David Baker ,  Brooke Fiala ,  Lance Joseph Stewart ,  Laurent Perez ,  Antonio Lanzavecchia ,  Jessica Marcandalli

IPC: C12N7/00 ,  C12N1/15 ,  C12N15/45 ,  A61K39/12 ,  A61K39/155 ,  C07K14/005 ,  A61P31/14 ,  B82Y5/00 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61P31/14 ,  B82Y5/00 ,  C12N7/00 ,  A61K2039/575 ,  C07K2319/735 ,  C12N2760/18022 ,  C12N2760/18322 ,  C12N2760/18522

Abstract: Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructures; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

公开(公告)号：US11485759B2

公开(公告)日：2022-11-01

申请号：US16427493

申请日：2019-05-31

Applicant: UNIVERSITY OF WASHINGTON

Inventor： David Baker ,  Jacob B. Bale ,  Neil P. King ,  William H. Sheffler ,  Daniel Ellis

IPC: C07K14/00

Abstract: Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.